Business Wire

Orchid Labs Introduces the Orchid™ Protocol and Tokens to Create an Internet Free from Surveillance and Censorship

Del

Orchid Labs Inc. has unveiled itself publicly today, along with the launch of the private alpha version of its Orchid Network accompanied by a whitepaper. The Orchid protocol is an open-source network intended to end internet surveillance and censorship, while protecting users’ personal data from being harvested by ISPs or other entities. Early in 2018, the blockchain-based Orchid network beta will launch to the public, enabling people across the world to freely communicate, collaborate, and access information.

According to Freedom House, two-thirds of all internet users live in countries where censorship and surveillance limit their ability to access information and communicate. For these individuals, a click or a share can mean imprisonment, or worse. And wherever you live, ISPs and VPNs are profiting from the sale of users’ most sensitive and private information.

Like many other dedicated people around the world, the founders of Orchid Labs are fighting to end these practices and bring an open and liberated internet to everyone in the world. The Orchid protocol is their contribution to this movement for internet freedom—meaning internet that can’t be controlled by corporations or governments and is open and accessible to all. The co-founders share more of their vision and the mission behind the open source technology project that contributes to this cause in the statement they published today.

Founding Team and Leadership

The Orchid founders, an established group of technologists, entrepreneurs, and blockchain experts, have been working in stealth since early 2017 to bring the technology to life. Collectively, the team has extensive expertise in security, networking, blockchain, and open-source software.

  • Stephen Bell: Steve started companies in Europe, the U.S., and China before founding Trilogy VC China, where he spent 10 years backing Chinese seed stage startups.
  • Brian J. Fox: Brian is an entrepreneur and open-source advocate, the first employee of the Free Software Foundation, and the author of the GNU Bash shell.
  • Jay Freeman: Jay is a software engineer and the developer of the Cydia software distribution platform used on millions of jailbroken iOS devices.
  • Gustav Simonsson: Gustav is an engineer and developer who helped launch Ethereum in 2015, working with core protocols, clients, and security auditing.
  • Dr. Steven Waterhouse: Steven is an experienced investor and entrepreneur, having co-founded RPX Corp, led cryptocurrency projects at Fortress and Pantera Capital, and the Honeycomb product at Sun Microsystems.

An Internet with Encrypted, Decentralized Architecture, Incentivized on the Blockchain

Orchid is building a new, surveillance-free layer on top of the internet. It’s fully decentralized, meaning that rather than traffic being routed through central authorities—like a user’s ISP or VPN—it's instead routed randomly through a network of nodes as bandwidth contributors sign up to share their surplus bandwidth. Users that want to access surveillance-free internet pay the bandwidth contributors in Orchid tokens in a free-market ecosystem. Orchid’s technology also ensures that central authorities can’t monitor traffic or payments, so it’s fully anonymous, for both the bandwidth consumer and the bandwidth contributor.

Advisors and Investors

To help provide counsel, Orchid Labs has enlisted a team of advisors with experience in cryptography and mission-driven projects. Orchid’s advisors include Gavin Wood, Founder & CTO at Parity Technologies; Dr. Dan Boneh, Professor and head of Cryptography at Stanford University’s Computer Science Department; and Alexander Lloyd, human rights advocate and Managing Director of Accelerator Ventures.

To support Orchid Labs and its mission, Orchid has raised a $4.7M seed SAFT (Simple Agreement for Future Tokens) from investors including Sequoia, Andreessen Horowitz, DFJ, PolyChain Capital, Metastable, Blockchain Capital, Crunchfund, Struck Capital, Compound VC, European Investor Richard Muirhead, and several other funds and angel investors.

To learn more about Orchid Labs, read their whitepaper, or sign up for more information, visit orchidprotocol.com.

About Orchid Labs Inc.

Orchid Labs Inc. is an open-source project committed to ending surveillance and censorship on the internet. The Orchid protocol uses an overlay network built upon the existing internet, which is driven by a peer-to-peer tokenized bandwidth exchange, creating a more inclusive, liberated internet. Orchid Labs was founded in 2017 by Stephen Bell, Brian J. Fox, Gustav Simonsson, Dr. Steven Waterhouse, and Jay Freeman. Orchid Labs is headquartered in San Francisco, California.

Contact information

CMO for Orchid Labs Inc.
Louise Callagy, 415-699-2963
press@orchidprotocol.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an